Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH3A1 | P30838 | 3/20 | 0.43 |
| ▸ | HPD | P32754 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | WRN | Q14191 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7996379 | 0.88 | ALDH3A1 (0.44) | ALDH3A1HPDALDH1A1LMNAGAA | |
| SCHEMBL7993331 | 0.88 | PTGS1 (0.44) | ALDH3A1HPDALDH1A1LMNAGAA | |
| SCHEMBL7995073 | 0.86 | ALDH3A1 (0.43) | ALDH3A1HPDALDH1A1LMNAGAA | |
| SCHEMBL6866312 | 0.81 | MAPT (0.44) | ALDH1A1LMNAGAAMAPTSMN1; SMN2 | |
| SCHEMBL8220420 | 0.80 | HPD (0.67) | HPDALDH1A1LMNAGAAMAPT | |
| SCHEMBL2047969 | 0.79 | ALDH1A1 (0.40) | ALDH3A1HPDALDH1A1LMNAGAA | |
| Mesotrione SCHEMBL29352201 | 0.77 | HPD (0.62) | ALDH3A1HPDALDH1A1LMNAGAA | |
| Mesotrione SCHEMBL22116 | 0.77 | HPD (0.62) | ALDH3A1HPDALDH1A1LMNAGAA | |
| Mesotrione SCHEMBL4895947 | 0.77 | HPD (0.62) | ALDH3A1HPDALDH1A1LMNAGAA | |
| SCHEMBL28465253 | 0.77 | ALDH3A1 (0.46) | ALDH3A1HPDALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023066372-A1 | AZAINDOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF, AND HERBICIDE | 山东先达农化股份有限公司 | 2023-04-27 | — | — | WO | disclosed |
| US-6809206-B2 | CONTACTING A PHENYL ESTER COMPOUND WITH A CYCLIC COMPOUND IN THE PRESENCE OF A SOURCE OF CYANIDE OR FLUORIDE TO PREPARE ACYLATED CYCLIC 1,3-DICARBONYL COMPOUNDS | E. I. DU PONT DE NEMOURS AND COMPANY | 2004-10-26 | — | — | US | disclosed |
| US-20030232984-A1 | Method for acylating cyclic compounds | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-12-18 | — | — | US | disclosed |
| US-20020049317-A1 | Method for acylating cyclic compounds | E.I. DU PONT DE NEMOURS AND COMPANY | 2002-04-25 | — | — | US | disclosed |
| EP-0968649-A1 | Adjuvants for novel dry herbicide formulations | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049317-A1 | Method for acylating cyclic compounds | LCAT, ACOT7, AGPAT5 | ALDH3A1 1699/4885HPD 1145/4885ALDH1A1 3181/4885 |
| US-20030232984-A1 | Method for acylating cyclic compounds | LCAT, ACOT7, AGPAT5 | ALDH3A1 1699/4885HPD 1145/4885ALDH1A1 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.